Expert Interview
A third opinion: Discussing the standard of care and the potential of Qulipta (Atogepant), a once-daily oral drug initially approved in 2021 for preventing episodic migraines that just got an expanded label to treat chronic migraines.
Ticker(s): ABBVInstitution: UCSF
- Chief of the Division of Headache Medicine and director of the Headache Center at UCSF Medical Center.
- Manages thousands of patients with migraine and specializes in the management of all forms of facial pain and headache.
- Author of numerous books on Neurology Clinical Case Studies and Headache and clinical and research interests include headache diagnosis and classification, emergency neurology, traumatic brain injury and medical education in neurology.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
